Global Health Ventures Inc. to Develop Rapidly Acting Low Cost Nicotine Replacement Therapy

Global Health Ventures Inc. to Develop Rapidly Acting Low Cost Nicotine Replacement Therapy

Global Health Ventures Inc. (OTCBB:GHLV) (the "Company"), a specialty pharma company focused on life style products is pleased to announce that it has started working on a new commercial product "Nico-Z". Nico-Z is a sublingual formulation of nicotine that is incorporated through our proprietary technology to deliver the product rapidly to the blood stream. It is anticipated that Nico-Z will enter the blood in high concentration within minutes. The product is in the form of a very small tablet to be kept under the tongue that disappears in less than a minute.

ABOUT NICO-Z

Addiction to tobacco, alcohol and hard drugs of controlled substance are a major cause of social, economic and health concerns in the modern society. Billions of dollars are spent on addiction and prevention each year. Last year the additive market was estimated at $10 billion and it is constantly growing due to stress and other complications. Nico-Z is a specially reformulated product that will reduce the need for tobacco. Nico-Z shall deliver much faster and far greater amount of nicotine than the patch, gum or inhalers in our opinion.

ABOUT GLOBAL HEALTH VENTURES

Global Health Ventures is a specialty pharma focused on the life style products. The company has a new proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastro-intestinal system, a process that can greatly reduce side effects associated with the drug. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach blood stream rapidly, producing maximal effect and having less of the unwanted side effects which are associated with the standard oral administration route drugs. X-Excite is presently in clinical trials in Europe. The Company also uses the same technology to deliver a vast number of other FDA approved drugs where they are needed to act rapidly. These include, stress relief, sleeping disorders, pain killers, anti-allergy medications, energy boosters and addiction replacement therapies.

Notice Regarding Forward Looking Statements - This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.